Atlas Trials

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study

Clinical trial NCT03875092 · COMPLETED

Trial details

NCT number
NCT03875092
Sponsor
Merck Sharp & Dohme LLC
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer
Start date
2017-04-21
Primary completion
2020-09-30
Enrollment
125

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.